We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Strix Group Plc | LSE:KETL | London | Ordinary Share | IM00BF0FMG91 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.80 | -1.10% | 72.00 | 72.70 | 73.40 | 72.00 | 72.00 | 72.00 | 60,939 | 11:13:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Manufacturing Industries,nec | 106.92M | 16.79M | 0.0768 | 9.38 | 157.47M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/5/2021 10:52 | ED - isn't that research paid for by Strix (or its shareholders)? | trident5 | |
28/5/2021 10:20 | #KETL this story just keeps getting better and better. Today we upgrade EPS expectations, yet PER is still at a discount to peers. Parity with those peers’ gives a fair value of 350p, 20% above today's price. | edmonda | |
27/5/2021 16:41 | To me this is a ten - fifteen year hold, re-invest dividends.......pens | bothdavis | |
27/5/2021 10:08 | I sold a little while back as I thought growth could only be bought in by pursuing non-core activities but notice that they're reporting particular strength in the regulated kettle controls segment; making me wonder whether I pulled the trigger too early. | trident5 | |
27/5/2021 09:46 | Yes you are correct. That would require a bumper H2. Growth is going to have to come from the non-kettle part of the group. Doing ok so far | dr biotech | |
27/5/2021 09:33 | Dr B - re-reading the RNS I think it's clear that they are forecasting 30% revenue growth for the full year. (They had a stronger 2H last year and as I said the FY was onely v marginally down on the previous year). | trident5 | |
27/5/2021 08:54 | Hi Trident No, it was down 21%. However it’s still ahead of forecast this morning, which is the key. FINANCIAL SUMMARY Adjusted results(1) -------------------- H1 2020 H1 2019 Change -------- -------- ------- GBPm GBPm %(3) Revenue 34.7 43.9 -21.0% | dr biotech | |
27/5/2021 08:41 | Well indeed. Everything on track including the important question of "can I raise my prices". That's a box ticked. Double revenues over 5 years is the plan and there are no negatives or difficulties reported. As ever the video presentation is great for anyone who is not sure or has questions. That global need fo rclean water is huge. Good execution form Strix is what is needed here. The rest will look after itself. | thorpematt | |
27/5/2021 07:52 | Zeus was forecasting 25% growth so 30% is ahead. The statement is very positive | melody9999 | |
27/5/2021 07:46 | Dr B - wasn't revenue in 2020 just v marginally down on the year before? | trident5 | |
27/5/2021 07:37 | Decent, but the growth is compared a weak 2020 where sales were down 20%. This represents a modest growth over 2019. | dr biotech | |
27/5/2021 07:35 | The revenue forecasts look a bit above mkt forecasts. | 18bt | |
27/5/2021 07:27 | Excellent news | nw99 | |
12/5/2021 09:00 | Thanks for the heads up. Was a well written piece. I liked the point that even though the Chinese ignore patent law people still want to buy safety equipment parts from the patent holder. Just put a comment in the comment section in the Times saying why I like the company. Get ready for a big demand for shares this morning ;)Signify sounded interesting too. But then there are a lot of energy efficient lighting companies out there selling LED bulbs etc. | scooper72 | |
12/5/2021 08:20 | Nice Buy recommendation in Tempus column in The Times today. | paulfred1 | |
28/4/2021 11:04 | In case you missed our webinar with Strix Group the recording and stockopedia report can be found here: To access the recording, you'll need to be a full member of ShareSoc, which is a not-for-profit organisation that supports individual shareholders and campaigns for shareholder rights. If you're not already a member you can join here: hxxps://www.sharesoc Once you've joined, you'll receive an invitation to register for our "members network" private social network, from where you'll be able to access the recording (and recordings/reports on 100s of other meetings). If you're already a member and have any difficulty accessing the report, please do not hesitate to contact us here: hxxps://www.sharesoc | sharesoc | |
13/4/2021 08:18 | Chart break soon | nw99 | |
08/4/2021 14:23 | Berenberg initiates at £3.30. Said 17% below value. Very positive in the medium to long term. | fromtheblue | |
05/4/2021 15:25 | For current investors and potential shareholders, we are hosting a webinar with Strix Group on the 20th April. Mark Bartlett – CEO will present. You can find out more about the webinar here: | sharesoc | |
01/4/2021 14:25 | Thanks missed that very good to know | dubai123 | |
01/4/2021 08:22 | You don't have to wait for today's - they have already done one presentation, including Q&A, which you can view here: Good chance for more questions today though. | sharw | |
01/4/2021 08:07 | I have registered to attend the live presentation from the CEO and CFO today on the investor meet company platform which starts at 2pm not sure if anyone else joining but great chance to ask questions etc | dubai123 | |
26/3/2021 13:30 | gnnmartin, It was Laica, acquired in October. Thanks for adding the extra detail. | alter ego | |
26/3/2021 13:22 | The large inventory impairment was explained in yesterday's Zoom. I've only recently started watching Strix, so forgive me not remembering names (and not looking them up!). Strix recently bought a company, and that company had over the years collected a lot of inventory that really should be written off. That Strix has now done. | gnnmartin | |
26/3/2021 12:22 | There is a potentially useful source of information over on Stocko but as I'm not a subscriber, I can't access it beyond the intro. Anyone here who does have access may care to share snippets e.g. comment about the reason for the large inventory impairment. | alter ego |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions